AgeX Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Biotechnology research into treatments for age-related degenerative conditions.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
AgeX Therapeutics is founded by Michael D. West as a subsidiary of BioTime, Inc., with backing from British billionaire investor Jim Mellon, to develop therapeutics for human longevity and age-related degenerative disease using its PureStem, HyStem, and induced Tissue Regeneration (iTR) platforms.
- Going-concern warning
With money running dry, AgeX announces substantial doubt about its ability to continue: it made $12,000 in revenue for the second quarter against $1.6 million in operating expenses, with about $702,000 in cash on hand and mounting Juvenescence debt.
- Merger with Serina
On March 26, 2024, AgeX completes its merger with Serina Therapeutics: following a reverse stock split, prior Serina shareholders own about 75% and prior AgeX shareholders about 25% of the combined company, which operates as Serina Therapeutics.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.